Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia

Schizophrenia Research

Volumn 158, Issue 1-3, 2014, Pages 213-222

  Hatta, Kotaro ^a,o   Otachi, Taro ^b   Fujita, Kiyoshi ^c   Morikawa, Fumiyoshi ^d   Ito, Shin ^e   Tomiyama, Hirofumi ^f   Abe, Takayuki ^g   Sudo, Yasuhiko ^h   Takebayashi, Hiroshi ⁱ   Yamashita, Toru ^j   Katayama, Shigemasa ^k   Nakase, Reiko ^l   Shirai, Yutaka ^m   Usui, Chie ^a   Nakamura, Hiroyuki ⁿ   Ito, Hiroto ^o   Hirata, Toyoaki ^g   Sawa, Yutaka ^p  

^a JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

^b Gunma Psychiatric Medical Center   (Japan)

^c Okehazama Hospital   (Japan)

^d Department of Psychiatry   (Japan)

^e Yamada Hospital   (Japan)

^f National Hospital Organization Hizen Psychiatric Center   (Japan)

^g Chiba Psychiatric Medical Center   (Japan)

^h Tosa Hospital   (Japan)

ⁱ Saitama Prefectural Psychiatric Hospital   (Japan)

^j Yamanashi Prefectural Kita Hospital   (Japan)

^k Seijin Hospital   (Japan)

^l Mie Prefectural Mental Health and Welfare Center   (Japan)

^m Hyogo Prefectural Amagasaki Hospital   (Japan)

ⁿ KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^o NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^p Sawa Hospital   (Japan)

more..

Author keywords

Add on; Combination; Early response; Emergency; Polypharmacy; Randomized clinical trial

Indexed keywords

OLANZAPINE; PROLACTIN; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERPROLACTINEMIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; OUTCOME ASSESSMENT; PARKINSONISM; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; ACUTE DISEASE; CLINICAL TRIAL; DRUG COMBINATION; JAPAN; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; TIME; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84906938642     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.07.015     Document Type: Article

References (26)

1. Ascher-Svanum H., Brnabic A., Lawson A.H., Kinon B.J., Stauffer V.L., Feldman P.D., Kelin K. Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia. Neuropsychiatr. Dis. Treat. 2012, 8:113-118.
2. Bigos K.L., Pollock B.G., Coley K.C., Miller D.D., Marder S.R., Aravagiri M., Kirshner M.A., Schneider L.S., Bies R.R. Sex, race, and smoking impact olanzapine exposure. J. Clin. Pharmacol. 2008, 48(2):157-165.
3. Bishara D., Olofinjana O., Sparshatt A., Kapur S., Taylor D., Patel M.X. Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J. Clin. Psychopharmacol. 2013, 33(3):329-335.
4. Derks E.M., Fleischhacker W.W., Boter H., Peuskens J., Kahn R.S. Antipsychotic drug treatment in first-episode psychosis should patients be switched to a different antipsychotic drug after 2, 4, or 6weeks of nonresponse?. J. Clin. Psychopharmacol. 2010, 30(2):176-180.
5. Essock S.M., Covell N.H., Davis S.M., Stroup T.S., Rosenheck R.A., Lieberman J.A. Effectiveness of switching antipsychotic medications. Am. J. Psychiatry 2006, 163(12):2090-2095.
6. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, US Dept of Health, Education, and Welfare, Bethesda.
7. Hatta K., Takahashi T., Nakamura H., Yamashiro H., Endo H., Fujii S., Fukami G., Masui K., Asukai N., Yonezawa Y. Abnormal physiological conditions in acute schizophrenic patients on emergency admission: dehydration, hypokalemia, leukocytosis and elevated serum muscle enzymes. Eur. Arch. Psychiatry Clin. Neurosci. 1998, 248(4):180-188.
8. Hatta K., Sato K., Hamakawa H., Takebayashi H., Kimura N., Ochi S., Sudo Y., Asukai N., Nakamura H., Usui C., Kawabata T., Hirata T., Sawa Y. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophr. Res. 2009, 113(1):49-55.
9. Hatta K., Otachi T., Sudo Y., Hayakawa T., Ashizawa Y., Takebayashi H., Hayashi N., Hamakawa H., Ito S., Nakase R., Usui C., Nakamura H., Hirata T., Sawa Y., Study Group J.A.S.T. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. Schizophr. Res. 2011, 128(1-3):127-135.
10. Hatta K., Otachi T., Sudo Y., Kuga H., Takebayashi H., Hayashi H., Ishii R., Kasuya M., Hayakawa T., Morikawa F., Hata K., Nakamura M., Usui C., Nakamura H., Hirata T., Sawa Y., JAST study group A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone. Psychiatry Res. 2012, 198(2):194-201.
11. Hatta K., Takebayashi H., Sudo Y., Katayama S., Kasuya M., Shirai Y., Morikawa F., Nakase R., Nakamura M., Ito S., Kuga H., Nakamura M., Ohnuma T., Usui C., Nakamura H., Hirata T., Sawa Y., for the JAST study group The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia. Psychiatry Res. 2013, 210(2):396-401.
12. Inada T. Evaluation and Diagnosis of Drug-induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to its Usage 1996, Seiwa Shoten Publishers, Tokyo.
13. Jones S.H., Thornicroft G., Coffey M., Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br. J. Psychiatry 1995, 166(5):654-659.
14. Kane J.M., Correll C.U., Goff D.C., Kirkpatrick B., Marder S.R., Vester-Blokland E., Sun W., Carson W.H., Pikalov A., Assunção-Talbott S. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J. Clin. Psychiatry 2009, 70(10):1348-1357.
15. Katona L., Czobor P., Bitter I. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: To switch or to combine? A nationwide study in Hungary. Schizophr. Res. 2014, 152(1):246-254.
16. Kay S.R., Opler L.A., Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Rating Manual 1991, Multi-Health System Inc., Toronto.
17. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Zhou W., Kapur S., Kane J.M. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010, 35(2):581-590.
18. Leucht S., Davis J.M., Engel R.R., Kissling W., Kane J.M. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr. Scand. 2009, 119(Suppl. 438):7-14.
19. Leucht S., Cipriani A., Spineli L., Mavridis D., Orey D., Richter F., Samara M., Barbui C., Engel R.R., Geddes J.R., Kissling W., Stapf M.P., Lässig B., Salanti G., Davis J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382(9896):951-962.
20. Levine S.Z., Leucht S. Early symptom response to antipsychotic medication as a marker of subsequent symptom change: An eighteen-month follow-up study of recent episode schizophrenia. Schizophr. Res. 2012, 141(2-3):168-172.
21. Li C., Xia J., Wang J. Risperidone dose for schizophrenia. Cochrane Database Syst. Rev. 2009, 4. (CD007474). 10.1002/14651858.CD007474.pub2.
22. Mauri M.C., Volonteri L.S., Colasanti A., Fiorentini A., De Gaspari I.F., Bareggi S.R. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin. Pharmacokinet. 2007, 46(5):359-388.
23. O'Gorman C., Kapur S., Kolluri S., Kane J. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies. Hum. Psychopharmacol. Clin. Exp. 2011, 26(4-5):282-290.
24. Patel M.X., Bowskill S., Couchman L., Lay V., Taylor D., Spencer E.P., Flanagan R.J. Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009. J. Clin. Psychopharmacol. 2011, 31(4):411-417.
25. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., McGee M.F., Simpson G.M., Stevens M.C., Lieberman J.A. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 2003, 29(1):15-31.
26. Wallwork R.S., Fortgang R., Hashimoto R., Weinberger D.R., Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr. Res. 2012, 137(1-3):246-250.